J&J strikes deal to buy Israeli biopharmaceutical firm

11/25/2008 | Forbes

Johnson & Johnson said Monday that it has agreed to purchase Israel-based Omrix Biopharmaceuticals for $438 million in cash. The acquisition is expected to benefit J&J's Ethicon unit, which already owns distribution rights in the U.S. and European Union for two of Omrix's biosurgical products.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC